Supriya Lifescience Share price target & analyst calls

₹842.6-30.65 (-3.51%)
As of 21 Oct 2026
No positional price targets right nowLast 1-year target: ₹800 from Deven Choksey, DRChoksey (22 Aug 2025) · target hit·38% historic hit rate on this stock
0
none open right now
—
no positional targets
38%
5 of 13 closed calls hit
13
all horizons, open and closed

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

All tips (13)

BUYTarget₹800
1 Year* · 22 Aug 2025 · entry ₹689.55 · via Institutional / Brokerage Researchexit ₹800
BUYTarget₹1,116
ICbyIDBI CapitalStop-loss hit
1–3 Months* · 2 Jul 2026 · entry ₹1,032 · via IDBI Capital Research Calls Telegramexit ₹992
BUYTarget₹1,090
1–3 Months* · 24 Jun 2026 · entry ₹941.2 · via NDTV Profit (Live)exit ₹906
BUYTarget₹1,085
ICbyIDBI CapitalStop-loss hit
1–3 Months · 23 Jun 2026 · entry ₹957.3 · via IDBI Capital Research Calls Telegramexit ₹906
BUYTarget₹1,030
1–3 Months* · 6 Jul 2026 · entry ₹865.2 · via Economic Times New Stock Recosexit ₹899.55
BUYTarget₹1,011
1–2 Weeks* · 24 Sept 2026 · entry ₹979 · via ET Now (Live)exit ₹1,011
BUYTarget₹980
1–2 Weeks* · 21 Sept 2026 · entry ₹933.75 · via CNBC Awaaz.exit ₹980
BUYTarget₹1,000
1–2 Weeks* · 21 Sept 2026 · entry ₹927.5 · via Business Todayexit ₹1,000
BUYTarget₹965
KBbyKush BohraTarget hit
1–2 Weeks* · 18 Sept 2026 · entry ₹908.95 · via NDTV Profit (Live)exit ₹965
BUYTarget₹1,020
KBbyKush BohraStop-loss hit
1–2 Weeks* · 29 Sept 2026 · entry ₹986 · via NDTV Profitexit ₹960
BUYTarget₹1,078
MBbyMadhu BansalStop-loss hit
1–2 Weeks* · 29 Sept 2026 · entry ₹986 · via CNBC Awaaz.exit ₹959
BUYTarget₹1,060
1–2 Weeks* · 28 Sept 2026 · entry ₹996.9 · via CNBC Awaaz.exit ₹978
BUYTarget₹960
1–2 Weeks* · 20 Aug 2026 · entry ₹820 · via Zee Business (Live)exit ₹843.05

* Horizon not stated by the source; assumed from how far the target is from the entry price.

Compare Pharmaceuticals & Biotechnology targets

Most-covered stocks in the sector · average 1-year target

See all Pharmaceuticals & Biotechnology analyst picks